{
  "Manifest": {
    "name": "Anestix – Anesthesiology & ICU Platform",
    "shortName": "Anestix",
    "description": "A global anesthesiology and ICU platform providing clinical guidelines, drug dosage calculators, sedation protocols, and more.",
    "screenshots": {
      "wideLabel": "Wide representation of operating room",
      "narrowLabel": "Narrow representation of operating room"
    },
    "shortcuts": {
      "dashboard": {
        "name": "Dashboard",
        "shortName": "Dashboard",
        "description": "Quick access to all sections"
      }
    }
  },
  "MetadataRoute": {
    "title": "Anestix – Advanced Anesthesiology & ICU Platform",
    "description": "Anestix is a global platform focusing on anesthesiology and ICU, offering clinical guidelines, drug dosage calculators, sedation protocols, and more.",
    "keywords": [
      "anesthesiology",
      "anesthesia",
      "ICU",
      "intensive care",
      "medical guidelines",
      "critical care",
      "drug dosage calculators",
      "fentanyl dosage",
      "noradrenaline dosage",
      "propofol dosage",
      "dopamine dosage",
      "actilyse dosage",
      "aldrete score",
      "apache II score",
      "four score",
      "gcs score",
      "nihss",
      "sofa score",
      "rass score",
      "sedation protocols",
      "bicarbonate deficit calculator",
      "plasma exchange calculator",
      "pediatric infusion rate",
      "creatinine clearance formula",
      "mechanical ventilation",
      "analgesia guidelines",
      "intubation",
      "advanced airway management",
      "medical calculators",
      "medicine",
      "Anestix"
    ]
  },
  "MetadataDashboard": {
    "title": "Dashboard",
    "description": "Quick access to all sections that are available "
  },
  "Units": {
    "kg_m2": "kg/m²",
    "kcal_day": "kcal/day",
    "ml_min": "mL/min",
    "ml_min_m2": "mL/min/1.73m²",
    "ml_hr": "mL/hr",
    "ml_kg_hr": "mL/kg/hr",
    "ml": "mL",
    "kg": "kg",
    "g": "g",
    "mg": "mg",
    "mcg": "mcg",
    "l": "L",
    "mg_dl": "mg/dL",
    "umol_l": "µmol/L",
    "mmol_l": "mmol/L",
    "meq_l": "mEq/L",
    "mm_hg": "mmHg",
    "cm_h2o": "cmH2O",
    "m": "m",
    "cm": "cm",
    "mm": "mm",
    "pct": "%",
    "bpm": "bpm",
    "years": "years",
    "h": "hours",
    "mcg_kg": "mcg/kg",
    "mcg_kg_min": "mcg/kg/min",
    "mcg_kg_hr": "mcg/kg/hr",
    "mg_per_min": "mg per min",
    "mg_hr": "mg/hr",
    "mg_kg": "mg/kg",
    "mg_kg_min": "mg/kg/min",
    "mg_kg_hr": "mg/kg/hr",
    "mcg_min": "mcg/min",
    "mg_ml": "mg/ml",
    "mcg_ml": "mcg/ml",
    "mcg_hr": "mcg/hr",
    "g_l": "g/L",
    "months": "months",
    "mg_day": "mg/day",
    "": ""
  },
  "Toasts": {
    "invalidRangeBoth": "Input value for \"{paramName}\" is out of allowed range. Please enter a value between {min, number} and {max, number} {unit}.",
    "invalidRangeMin": "Input value for \"{paramName}\" is below the allowed minimum of {min, number} {unit}.",
    "invalidRangeMax": "Input value for \"{paramName}\" is above the allowed maximum of {max, number} {unit}.",
    "overDosage": "Input value for \"{paramName}\" exceeds the recommended dosage of {maxValue, number} {unit} as per the documentation."
  },
  "Home": {
    "title": "Anestix",
    "welcome": "Welcome to the Anesthesiologist's guide",
    "enterPlatform": "Enter Platform",
    "platformDescription": "Your comprehensive platform for anesthesiology professionals",
    "": ""
  },
  "SearchBar": {
    "search": "Search",
    "noResults": "No Results"
  },
  "Features": {
    "comprehensive_resources": {
      "title": "Comprehensive Resources",
      "description": "Access a wide range of anesthesiology resources, clinical guidelines, and research papers."
    },
    "interactive_scores": {
      "title": "Interactive score pages",
      "description": "Various medical scores to estimate risk / prognosis for ICU patients"
    },
    "medical_calculators": {
      "title": "Calculators for drug dosages & formulas",
      "description": "Utilize built-in calculators for risk assessments, dosage dosages, and more to support informed clinical decision-making."
    }
  },
  "Dashboard": {
    "title": "Dashboard",
    "no_items": "There are no items available right now",
    "explore": "Explore",
    "underDev": "Under development",
    "home": "Home",
    "metaTitleDefault": "Section",
    "metaDescDefault": "Navigation items page",
    "": "",
    "score-list": {
      "title": "Scores",
      "description": "Empower your clinical decisions with our comprehensive range of medical scores, including RASS, FOUR, Glasgow, and more. Each section provides detailed scoring guides."
    },
    "calculators": {
      "title": "Calculators",
      "description": "Utilize our precision tools to compute drug dosages and other vital parameters. Each calculator comes with in-depth guides and safety tips to ensure accurate, patient-specific outcomes.."
    },
    "ultrasound": {
      "title": "Ultrasound",
      "description": "Here you'll find detailed protocols and guidelines for ultrasound-assisted procedures, including nerve block visualization."
    },
    "skills": {
      "title": "Skills",
      "description": "Dive into in‑depth information on medical procedures and practical skills across many sub‑sections."
    }
  },
    "SubItemsList": {
      "no_items": "There are no items available right now",
      "": "",
      "rass": {
        "title": "RASS",
        "description": "Assesses sedation and agitation levels in critically ill patients to guide sedation management"
      },
      "four": {
        "title": "FOUR Score",
        "description": "Evaluates consciousness with a focus on brainstem reflexes and respiratory patterns for a detailed neurological assessment"
      },
      "gcs": {
        "title": "Glasgow Coma Scale (GCS)",
        "description": "Measures the level of consciousness following head injuries or neurological impairments"
      },
      "aldrete": {
        "title": "Aldrete Score",
        "description": "Determines a patient's readiness for discharge from post-anesthesia recovery by assessing activity, respiration, and consciousness"
      },
      "sofa": {
        "title": "SOFA Score",
        "description": "Used to track a patient’s status during their stay in an intensive care unit (ICU) to determine the extent of organ function or rate of failure"
      },
      "nihss": {
        "title": "NIHSS",
        "description": "Quantifies neurological deficits to evaluate stroke severity and guide treatment"
      },
      "apacheii": {
        "title": "Apache II Score",
        "description": "Scores illness severity and predicts mortality in ICU patients based on acute physiology and chronic health data"
      },
      "wells": {
        "title": "Wells Score",
        "description": "Score for assessing the clinical probability of pulmonary embolism are used in stable patients (without shock, hypotension) with suspected PE"
      },
      "pesi": {
        "title": "PESI Score",
        "description": "The PESI (Pulmonary Embolism Severity Index) score allows assessing the risk of 30-day mortality in patients with PE"
      },
      "lee": {
        "title": "RCRI Score (Index Lee)",
        "description": "Provides individualized risk stratification prior to undergoing surgery, which can be helpful in discussions of informed consent"
      },
      "caprini": {
        "title": "Caprini Score",
        "description": "The Caprini Score is a validated risk assessment tool to estimate the risk of venous thromboembolism (VTE) based on patient-specific risk factors"
      },
      "hasbled": {
        "title": "HAS-BLED Score",
        "description": "Scoring system developed to assess 1-year risk of major bleeding in people taking anticoagulants for atrial fibrillation (AF)"
      },
      "news2": {
        "title": "NEWS 2 Score",
        "description": "The score for assessing the severity of patients with acute respiratory syndromes is aimed to a greater extent at assessing the current condition of the patient and to a lesser extent at assessing the prognosis of the disease"
      },
      "pgcs": {
        "title": "Pediatric Glasgow Coma Scale (pGCS)",
        "description": "Use for children 2 years and younger only. For older children, use the standard Glasgow Coma Scale (GCS)."
      },
      "phoenix": {
        "title": "Phoenix Sepsis Score",
        "description": "A tool to assess life-threatening organ dysfunction due to infection in pediatric patients."
      },
      "apgar": {
        "title": "Apgar Score",
        "description": "A quick test performed on a baby at 1 and 5 minutes after birth to determine physical condition"
      },
      "qsofa": {
        "title": "qSOFA Score",
        "description": "Rapid assessment tool for sepsis without the need for laboratory tests, making it particularly useful in urgent and resource-limited settings."
      },
      "drug-calculators": {
        "title": "Drug dosage calculators",
        "description": "Use our drug dosage calculators for accurate medication dosing, tailored to patient-specific parameters"
      },
      "formula-calculators": {
        "title": "Formula calculator",
        "description": "Employ our formula calculator to compute essential medical formulas with precision"
      },
      "nerve-block": {
        "title": "Peripheral nerve block",
        "description": "Access guidelines and protocols for performing peripheral nerve blocks with ultrasound guidance"
      },
      "intubation": {
        "title": "Intubation",
        "description": "Explore detailed instructions and techniques for safe and effective intubation procedures"
      }
    },
    "LinksList": {
      "actilyse": "Actilyse",
      "bmi": "Body mass index",
      "calories": "Daily calorie requirements",
      "creatinine": "Creatinine clearance",
      "waterBalance": "Daily water balance",
      "dailyDiuresis": "Hourly diuresis rate",
      "algover": "Algover index",
      "plasmaExchange": "Plasma exchange calculator",
      "thiopental": "Thiopental",
      "propofol": "Propofol",
      "ketamine": "Ketamine",
      "gomh": "Sodium Oxybutyrate",
      "fentanyl": "Fentanyl",
      "ditilin": "Ditilin",
      "atracurium": "Atracurium",
      "dexon": "Dexamethasone",
      "naloxone": "Naloxone",
      "noradrenaline": "Noradrenaline (Norepinephrine)",
      "dopamine": "Dopamine",
      "nitroglycerin": "Nitroglycerin",
      "sufentanil": "Sufentanil",
      "rocuronium": "Rocuronium",
      "pediatricInfusion": "Pediatric infusion rate",
      "remifentanyl": "Remifentanil",
      "solutionConcentration": "Solution Concentration",
      "solutionVolume": "Solution Volume",
      "devine": "Ideal Body Weight",
      "map": "Mean Arterial Pressure (MAP)",
      "potassiumDeficit": "Potassium Deficit",
      "bicarbonateDeficit": "Bicarbonate Deficit",
      "ett": "Size of endotracheal tube (ETT) in pediatric patients (1 to 12 years)",
      "solutionDilution": "Solution Dilution Calculator",
      "anionGap": "Anion Gap",
      "midazolam": "Midazolam"
  },
  "ScorePage": {
    "criteria": "Criteria",
    "respOptions": "Response Options",
    "totalScore": "Total Score: ",
    "result": "Result: ",
    "not_found": "Score configuration not found",
    "yes": "Yes",
    "no": "No",
    "score": "point",
    "select_an_option": "Select an option",
    "metaTitleDefault": "Score",
    "metaDescDefault": "Medical score for ICU and anesthesiology",
    "": "",
    "glasgow": {
      "name": "Glasgow Coma Score",
      "description": "Fundamental component for monitoring neurological status. Regular GCS assessments allow healthcare providers to detect changes in a patient’s level of consciousness, facilitating timely interventions. For instance, a decrease in GCS score may indicate deterioration, prompting further diagnostic evaluation or therapeutic measures.",
      "criteria": {
        "eye": {
          "label": "Eye Opening",
          "option1": "No eye opening",
          "option2": "Eye opening to pain",
          "option3": "Eye opening to voice",
          "option4": "Spontaneous eye opening"
        },
        "verbal": {
          "label": "Verbal Response",
          "option1": "No verbal response",
          "option2": "Incomprehensible sounds",
          "option3": "Pronounces individual words",
          "option4": "Pronounces isolated phrases, slurred speech",
          "option5": "Oriented"
        },
        "motor": {
          "label": "Motor Response",
          "option1": "No motor response",
          "option2": "Abnormal extension to pain",
          "option3": "Abnormal flexion to pain",
          "option4": "Withdrawal from pain",
          "option5": "Appropriate movement to pain",
          "option6": "Obeys commands"
        }
      },
      "result": {
        "clear": "Clear consciousness",
        "moderateStunning": "Moderate obtundation",
        "deepStunning": "Deep obtundation",
        "stupor": "Stupor",
        "moderateComa": "Moderate coma",
        "deepComa": "Deep coma",
        "terminalComa": "Terminal coma"
      },
      "extraDescription": "While the GCS is widely used, it has limitations, especially in cases involving intubated patients, severe facial injuries, or when assessing young children. In such scenarios, alternative or modified assessment tools may be employed to ensure accurate evaluation."
    },
    "four": {
      "name": "FOUR Score",
      "description": "FOUR score is based on the bare minimum of tests necessary for assessing a patient with altered consciousness, it includes much important information that is not assessed by the GCS, including measurement of brainstem reflexes; determination of eye opening, blinking, and tracking; a broad spectrum of motor responses; and the presence of abnormal breath rhythms.",
      "criteria": {
        "eye": {
          "label": "Eye Response",
          "option0": "No response",
          "option1": "Eye opening to pain",
          "option2": "Eye opening to voice",
          "option3": "Spontaneous eye opening without tracking",
          "option4": "Spontaneous eye opening with blinking and tracking"
        },
        "motor": {
          "label": "Motor Response",
          "option0": "Absent or myoclonus",
          "option1": "Extension to pain",
          "option2": "Flexion to pain",
          "option3": "Localizes pain",
          "option4": "Obeys commands"
        },
        "brainstem": {
          "label": "Brainstem Reflexes",
          "option0": "Pupillary, corneal, and cough reflexes absent",
          "option1": "Pupillary and corneal reflexes absent",
          "option2": "Either pupillary or corneal reflex absent",
          "option3": "One pupil dilated and unreactive to light",
          "option4": "Pupillary and corneal reflexes preserved"
        },
        "respiration": {
          "label": "Respiration",
          "option0": "Mechanical ventilation or apnea",
          "option1": "Mechanical with spontaneous breaths",
          "option2": "Spontaneous, irregular breathing",
          "option3": "Cheyne-Stokes respiration",
          "option4": "Spontaneous, normal, effective breathing"
        }
      },
      "result": {
        "clear": "Clear consciousness",
        "moderateStupor": "Moderate stupor",
        "deepStupor": "Deep stupor",
        "stupor": "Stupor",
        "comaI": "Coma I (moderate)",
        "comaII": "Coma II (deep)",
        "comaIII": "Coma III (extreme), death of the cerebral cortex"
      },
      "extraDescription": "Unlike the Glasgow Coma Scale, the FOUR Score evaluates brainstem activity and respiratory patterns, allowing better assessment of severe neurological states. With a 0–16 range, it offers clearer insight even when verbal response isn't measurable."
    },
    "rass": {
      "name": "RASS Score",
      "description": "The RASS (Richmond Agitation-Sedation Score) is used in anesthesiology and intensive care to describe the degree of patient aggression or the level of depth of sedation",
      "criteria": {
        "alertness": {
          "label": "Alertness",
          "negative5": "No response to voice or physical stimulation",
          "negative4": "No response to voice, but movement to physical stimulation",
          "negative3": "Any movement (without eye contact) in response to voice",
          "negative2": "Brief awakening with eye contact (<10 seconds)",
          "negative1": "Sustained awakening with eye contact upon voice stimulation",
          "zero": "Alert and calm",
          "positive1": "Restless or anxious",
          "positive2": "Pulls or removes tubes/catheters or acts aggressively",
          "positive3": "Frequent non-purposeful movements or ventilator dyssynchrony",
          "positive4": "Excessively aggressive; immediate danger to personnel"
        }
      },
      "result": {
        "unarousable": "Unarousable",
        "deepSedation": "Deep sedation",
        "moderateSedation": "Moderate sedation",
        "lightSedation": "Light sedation",
        "drowsy": "Drowsy",
        "alertAndCalm": "Alert and calm",
        "restless": "Restless",
        "agitated": "Agitated",
        "veryAgitated": "Very agitated",
        "combative": "Combative"
      },
      "extraDescription": "It is recommended to perform RASS assessment in all patients admitted to hospital, as well as in all patients on mechanical ventilation.\n• In patients with RASS of -3 points or less, sedation should be reduced or changed until reaching -2 to 0 points on the RASS scale;\n• Patients with RASS of 2 points or more are insufficiently sedated and require determination of the cause of agitation (anxiety disorder, delirium, pain) and deepening of sedation until reaching -2 to 0 points on the RASS scale;\n• If possible, excessive deepening of sedation (less than -2 points on the RASS scale) should be avoided unless there are indications for it."
    },
    "aldrete": {
      "name": "Modified Aldrete Score",
      "description": "The Modified Aldrete Score is used in post-anesthesia care units (PACU) to assess when a patient has recovered sufficiently from anesthesia to be safely discharged to a regular hospital ward. It evaluates five domains: activity, respiration, circulation, consciousness, and oxygen saturation.",      "criteria": {
        "activity": {
          "label": "Activity",
          "option0": "No movement on command",
          "option1": "Movement in two extremities on command",
          "option2": "Movement in all extremities on command"
        },
        "breathing": {
          "label": "Breathing",
          "option0": "Apnea",
          "option1": "Dyspnea",
          "option2": "Deep breathing with strong cough"
        },
        "bloodPressure": {
          "label": "Blood Pressure",
          "option0": "50% or more deviation from pre-anesthesia level",
          "option1": "20-49% deviation from pre-anesthesia level",
          "option2": "Within 20% of pre-anesthesia level"
        },
        "consciousness": {
          "label": "Consciousness",
          "option0": "Depressed consciousness",
          "option1": "Response to stimulation",
          "option2": "Clear"
        },
        "spo2": {
          "label": "SpO2",
          "option0": "Less than 90% with oxygen insufflation",
          "option1": "More than 90% with oxygen insufflation",
          "option2": "Greater than 92%"
        }
      },
      "result": {
        "readyForTransfer": "Ready for transfer",
        "notReadyForTransfer": "Not ready for transfer"
      },
      "extraDescription": "Widely used in PACUs, the Modified Aldrete Score standardizes discharge criteria by evaluating motor activity, respiration, hemodynamics, consciousness, and oxygenation. A score ≥9 suggests readiness for ward transfer. It helps reduce post-anesthesia complications by identifying residual sedation, hypoventilation, or hemodynamic instability early. Reassessment every 10–15 minutes is recommended until criteria are met."
    },
    "sofa": {
      "name": "Sequential Organ Failure Assessment (SOFA) Score",
      "description": "The SOFA score is used to track a patient’s status during their stay in an intensive care unit (ICU) to determine the extent of organ function or rate of failure. It assesses six organ systems and assigns a score from 0 to 4 for each, with higher scores indicating greater dysfunction.",
      "criteria": {
        "respiratory": {
          "label": "Respiratory (mmHg) *",
          "option0": "• P/F ratio: >400\nor\n• S/F ratio: >302",
          "option1": "• P/F ratio: <400\nor\n • S/F ratio: <302",
          "option2": "• P/F ratio: <300\nor\n • S/F ratio: <221",
          "option3": "• P/F ratio: <200\nor\n • S/F ratio: <142\nwith MV (CPAP included)",
          "option4": "• P/F ratio: <100\nor\n • S/F ratio: <67\nwith MV (CPAP included)"
        },
        "platelets": {
          "label": "Platelets (×10³/mcL)",
          "option0": "≥ 150",
          "option1": "< 150",
          "option2": "< 100",
          "option3": "< 50",
          "option4": "< 20"
        },
        "bilirubin": {
          "label": "Bilirubin",
          "option0": "< 1.2 mg/dL\n(20 μmol/L)",
          "option1": "1.2–1.9 mg/dL\n(20–32 μmol/L)",
          "option2": "2.0–5.9 mg/dL\n(33–101 μmol/L)",
          "option3": "6.0–11.9 mg/dL\n(102–204 μmol/L)",
          "option4": "> 12.0 mg/dL\n(204 μmol/L)"
        },
        "cardiovascular": {
          "label": "Cardiovascular (doses in mcg/kg/min)",
          "option0": "MAP ≥ 70 mm Hg",
          "option1": "MAP < 70 mm Hg",
          "option2": "• Dopamine < 5\nor\n• any Dobutamine dose",
          "option3": "• Dopamine 5.1–15\nor\n• Epinephrine ≤ 0.1\nor\n• Norepinephrine ≤ 0.1",
          "option4": "• Dopamine > 15\nor\n• Epinephrine > 0.1\nor\n• Norepinephrine > 0.1"
        },
        "gcs": {
          "label": "Glasgow Coma Score",
          "option0": "15 points",
          "option1": "13–14 points",
          "option2": "10–12 points",
          "option3": "6–9 points",
          "option4": "< 6 points"
        },
        "creatinine": {
          "label": "Creatinine or Urine output",
          "option0": "< 1.2 mg/dL\n(110 μmol/L)",
          "option1": "1.2–1.9 mg/dL\n(110–170 μmol/L)",
          "option2": "2.0–3.4 mg/dL\n(171–299 μmol/L)",
          "option3": "3.5–4.9 mg/dL\n(300–400 μmol/L)\nor\n< 500 ml/day",
          "option4": "> 5.0 mg/dL\n(440 μmol/L)\nor\n< 200 ml/day"
        }
      },
      "result": {
        "mortality0": "Mortality: initial score 0.0%, highest score 0.0%",
        "mortality1": "Mortality: initial score 6.4%, highest score 1.5%",
        "mortality2": "Mortality: initial score 20.2%, highest score 6.7%",
        "mortality3": "Mortality: initial score 21.5%, highest score 18.2%",
        "mortality4": "Mortality: initial score 33.3%, highest score 26.3%",
        "mortality5": "Mortality: initial score 50.0%, highest score 45.8%",
        "mortality6": "Mortality: initial score 95.2%, highest score 80.0%",
        "mortality7": "Mortality: initial score 95.2%, highest score 89.7%"
      },
      "extraDescription": "An increase in SOFA score ≥2 points in the presence of suspected infection is one of the criteria for diagnosing sepsis according to Sepsis-3 guidelines.\n\n* Respiratory:\n- P/F ratio calculated as: PaO2 / FiO2 as decimal\n- S/F ratio calculated as: SpO2 / FiO2 as decimal"
    },
    "nihss": {
      "name": "NIH Stroke Score",
      "description": "A standardized tool for assessing stroke severity and neurological deficits.",
      "extraDescription": "Note:\n- For Level of Consciousness, observe the patient’s alertness, ask two questions (e.g., 'What month is it?' and 'How old are you?'), and test simple commands (open/close eyes, grip/release hand).\n- For Best Gaze, have the patient follow a moving object horizontally.\n- For Visual Fields, perform a confrontation test in all quadrants and note any partial or complete field loss.\n- For Facial Palsy, ask the patient to smile, raise eyebrows, and close eyes to check for asymmetry.\n- For Motor responses, test each arm by having it extended (90° if sitting or 45° if supine) for 10 seconds and each leg by raising it to 30° for 5 seconds, noting any drift, decreased effort, or absence of movement.\n- For Limb Ataxia, have the patient perform finger-to-nose and heel-to-shin tests, scoring only when incoordination exceeds weakness.\n- For Best Language, assess the ability to describe a picture, name objects, or read sentences, scoring based on fluency and comprehension.\n- For Dysarthria, ask the patient to repeat words to evaluate speech clarity.\n- Finally, for Extinction and Inattention, use simultaneous stimulation to check for neglect.",
      "criteria": {
        "loc": {
          "label": "Level of Consciousness",
          "option0": "Alert; keenly responsive",
          "option1": "Not alert; arousable with minor stimulation",
          "option2": "Not alert; obtunded",
          "option3": "Unresponsive; only reflex movements"
        },
        "locQuestions": {
          "label": "LOC - Questions",
          "option0": "Answers both questions correctly",
          "option1": "Answers one question correctly",
          "option2": "Answers neither correctly"
        },
        "locCommands": {
          "label": "LOC - Commands",
          "option0": "Follows both commands",
          "option1": "Follows one command",
          "option2": "Follows neither command"
        },
        "bestGaze": {
          "label": "Best Gaze",
          "option0": "Normal",
          "option1": "Partial gaze palsy",
          "option2": "Forced deviation/total gaze palsy"
        },
        "visualFields": {
          "label": "Visual Fields",
          "option0": "No visual loss",
          "option1": "Partial hemianopsia",
          "option2": "Complete hemianopsia",
          "option3": "Bilateral hemianopsia/blindness"
        },
        "facialPalsy": {
          "label": "Facial Palsy",
          "option0": "Normal symmetry",
          "option1": "Minor asymmetry",
          "option2": "Partial paralysis",
          "option3": "Complete paralysis"
        },
        "motorArmLeft": {
          "label": "Motor - Left Arm",
          "option0": "No drift; holds for 10 sec",
          "option1": "Drift before 10s",
          "option2": "Falls before 10s",
          "option3": "No effort against gravity",
          "option4": "No movement"
        },
        "motorArmRight": {
          "label": "Motor - Right Arm",
          "option0": "No drift; holds for 10 sec",
          "option1": "Drift before 10s",
          "option2": "Falls before 10s",
          "option3": "No effort against gravity",
          "option4": "No movement"
        },
        "motorLegLeft": {
          "label": "Motor - Left Leg",
          "option0": "No drift; holds for 10 sec",
          "option1": "Drift before 5",
          "option2": "Falls before 5",
          "option3": "No effort against gravity",
          "option4": "No movement"
        },
        "motorLegRight": {
          "label": "Motor - Right Leg",
          "option0": "No drift; holds for 5 sec",
          "option1": "Drift before 5",
          "option2": "Falls before 5",
          "option3": "No effort against gravity",
          "option4": "No movement"
        },
        "limbAtaxia": {
          "label": "Limb Ataxia",
          "option0": "Absent",
          "option1": "Ataxia in one limb",
          "option2": "Ataxia in two or more limbs"
        },
        "sensory": {
          "label": "Sensory",
          "option0": "Normal sensation",
          "option1": "Mild-to-moderate loss",
          "option2": "Severe or total loss"
        },
        "bestLanguage": {
          "label": "Best Language",
          "option0": "Normal",
          "option1": "Mild-to-moderate aphasia",
          "option2": "Severe aphasia",
          "option3": "Mute or global aphasia"
        },
        "dysarthria": {
          "label": "Dysarthria",
          "option0": "Normal speech",
          "option1": "Mild-to-moderate slurring",
          "option2": "Severe slurring or mute"
        },
        "extinctionInattention": {
          "label": "Extinction & Inattention",
          "option0": "No abnormality",
          "option1": "Neglect in one modality",
          "option2": "Profound neglect in multiple modalities"
        }
      },
      "result": {
        "noStroke": "No stroke",
        "minorStroke": "Minor stroke",
        "moderateStroke": "Moderate stroke",
        "moderateSevereStroke": "Moderate-severe stroke",
        "severeStroke": "Severe stroke"
      }
    },
    "apacheii": {
      "name": "APACHE II Score",
      "description": "APACHE II score is a general measure of disease severity and mortality risk based on current physiologic measurements, age & previous health conditions.\n\nNOTE: Some of the presented options have multiple possible ranges! Choose worst values in past 24h.",
      "criteria": {
        "age": {
          "label": "Age, years",
          "option0": "≤44",
          "option1": "45-54",
          "option2": "55-64",
          "option3": "65-74",
          "option4": ">74"
        },
        "chronicHealth": {
          "label": "Chronic organ dysfunction or immunocompromise",
          "option0": "No",
          "option1": "Yes, elective postoperative",
          "option2": "Yes, nonoperative or emergency postoperative"
        },
        "temperature": {
          "label": "Temperature (°C)",
          "option0": "36-38.5°C",
          "option1": "• 34-36°C\nor\n• 38.5-39°C",
          "option2": "32-34°C",
          "option3": "• 30-32°C\nor\n• 39 to <41°C",
          "option4": "• ≥41°C\nor\n• <30°C"
        },
        "map": {
          "label": "Mean Arterial Pressure (mmHg)",
          "option0": "70-109 mmHg",
          "option1": "• 110-129 mmHg\nor\n• 50-69 mmHg",
          "option2": "130-159 mmHg",
          "option3": "• >159 mmHg\nor\n• ≤49 mmHg"
        },
        "heartRate": {
          "label": "Heart Rate (bpm)",
          "option0": "70-110 bpm",
          "option1": "• 110-140 bpm\nor\n• 55-70 bpm",
          "option2": "• 140-180 bpm\nor\n• 40-55 bpm",
          "option3": "• ≥180 bpm\nor\n• <40 bpm"
        },
        "respiratoryRate": {
          "label": "Respiratory Rate (breaths/min)",
          "option0": "12-25 breaths/min",
          "option1": "• 10-12 breaths/min\nor\n• 25-35 breaths/min",
          "option2": "6-10 breaths/min",
          "option3": "35-50 breaths/min",
          "option4": "• ≥50 breaths/min\nor\n• 6 breaths/min"
        },
        "oxygenation": {
          "label": "Oxygen saturation or A–a gradient (use PaO2 if FiO2 <50%, otherwise use A-a gradient)",
          "option0": "• PaO2 >70 mmHg\nor\n• A–a gradient <200 mmHg",
          "option1": "PaO2 61-70 mmHg",
          "option2": "A–a gradient 200-349 mmHg",
          "option3": "• PaO2 55-60 mmHg\nor\n• A–a gradient 350-499 mmHg",
          "option4": "• PaO2 <55 mmHg\nor\n• A–a gradient >499 mmHg"
        },
        "ph": {
          "label": "Arterial pH",
          "option0": "7.33-7.50",
          "option1": "7.50-7.60",
          "option2": "7.25-7.33",
          "option3": "• 7.60-7.70\nor\n• 7.15-7.25",
          "option4": "• ≥7.70\nor\n• <7.15"
        },
        "sodium": {
          "label": "Serum Sodium (mmol/L)",
          "option0": "130-150",
          "option1": "150-155",
          "option2": "• 155-160\nor\n• 120-130",
          "option3": "• 160-180\nor\n• 111-120",
          "option4": "• ≥180\nor\n• 111"
        },
        "potassium": {
          "label": "Serum Potassium (mmol/L)",
          "option0": "3.5-5.5",
          "option1": "• 5.5-6.0\nor\n• 3.0-3.5",
          "option2": "2.5-3.0",
          "option3": "6.0-7.0",
          "option4": "• ≥7.0\nor\n• 2.5"
        },
        "creatinine": {
          "label": "Serum Creatinine (µmol/L)",
          "option0": "53–133",
          "option1": "• Less than 53\nor\n• 133–177 (CKI)",
          "option2": "177–310 (CKI)",
          "option3": "• 133–177 (AKI)\nor\n• ≥310 (CKI)",
          "option4": "177–310 (AKI)",
          "option5": "≥310 (AKI)"
        },
        "hematocrit": {
          "label": "Hematocrit (%)",
          "option0": "30-46%",
          "option1": "46-50%",
          "option2": "• 50-60%\nor\n• 20-30%",
          "option3": "• ≥60%\nor\n• <20%"
        },
        "wbc": {
          "label": "Total WBC (×10³/mm³)",
          "option0": "3-15",
          "option1": "15-20",
          "option2": "• 20-40\nor\n• 1-3",
          "option3": "• ≥40\nor\n• <1"
        },
        "gcs": {
          "label": "Glasgow Coma Scale (GCS)"
        }
      },
      "result": {
        "mortality0to4": "Estimated in-hospital mortality: 4% nonoperative / 1% postoperative",
        "mortality5to9": "Estimated in-hospital mortality: 8% nonoperative / 3% postoperative",
        "mortality10to14": "Estimated in-hospital mortality: 15% nonoperative / 7% postoperative",
        "mortality15to19": "Estimated in-hospital mortality: 25% nonoperative / 12% postoperative",
        "mortality20to24": "Estimated in-hospital mortality: 40% nonoperative / 30% postoperative",
        "mortality25to29": "Estimated in-hospital mortality: 55% nonoperative / 35% postoperative",
        "mortality30to34": "Estimated in-hospital mortality: 73% nonoperative / 73% postoperative",
        "mortality35plus": "Estimated in-hospital mortality: 85% nonoperative / 88% postoperative"
      },
      "extraDescription": "Minimum 0 and maximum 71; increasing score is associated with an increasing risk of hospital death.\nThe advantage of the APACHE is that it can be used throughout the patient’s hospital course in monitoring the patient’s response to therapy. \n\n* Chronic Organ Insufficiency: \n• Liver insufficiency: Biopsy-proven cirrhosis, documented portal hypertension, upper GI bleeding due to portal hypertension, or prior hepatic failure/encephalopathy/coma.\n• Cardiovascular: NYHA Class IV.\n• Respiratory: Severe restrictive/obstructive/vascular disease causing major exercise limitations, chronic hypoxia, hypercapnia, polycythemia, pulmonary hypertension (>40 mmHg), or respirator dependence.\n• Renal: Receiving chronic dialysis.\n• Immuno-depression: History of immunosuppressive therapy, chemotherapy, radiation, long-term or recent high-dose steroids, or advanced immunosuppressive diseases (e.g. leukemia, lymphoma, AIDS)."
    },
    "wells": {
      "name": "Wells Score",
      "description": "A clinical prediction rule used to estimate the probability of pulmonary embolism (PE).",
      "criteria": {
        "dvtSigns": {
          "label": "Clinical signs of Deep Vein Thrombosis (DVT)",
          "option0": "No",
          "option1": "Yes"
        },
        "alternativeDiagnosis": {
          "label": "Alternative diagnosis less likely than PE",
          "option0": "No",
          "option1": "Yes"
        },
        "heartRate": {
          "label": "Heart rate ≥ 100 bpm",
          "option0": "No",
          "option1": "Yes"
        },
        "recentSurgeryImmobilization": {
          "label": "Surgery or immobilization within the last 4 weeks",
          "option0": "No",
          "option1": "Yes"
        },
        "previousVTE": {
          "label": "Previous PE or DVT",
          "option0": "No",
          "option1": "Yes"
        },
        "hemoptysis": {
          "label": "Hemoptysis",
          "option0": "No",
          "option1": "Yes"
        },
        "malignancy": {
          "label": "Active cancer (treated in the last 6 months or on palliative care)",
          "option0": "No",
          "option1": "Yes"
        }
      },
      "result": {
        "lowProbability": "Low probability of PE (0-1 points): D-dimer testing is recommended. If negative, consider stopping further workup; if positive, CT pulmonary angiography is indicated.",
        "intermediateProbability": "Intermediate probability of PE (2-6 points): D-dimer testing is recommended. If negative, consider stopping further workup; if positive, CT pulmonary angiography is indicated.",
        "highProbability": "High probability of PE (≥7 points): CT pulmonary angiography is indicated."
      },
      "extraDescription": "Alternatively, a two-tier interpretation can be used: 0-4 points indicate PE unlikely; ≥5 points indicate PE likely."
    },
    "pesi": {
      "name": "PESI Score",
      "description": "The PESI Score is used to stratify risk in patients diagnosed with pulmonary embolism, helping to determine the severity of their condition and guide treatment decisions.",
      "criteria": {
        "age": "Age (in years)",
        "gender": {
          "label": "Gender",
          "option0": "Female",
          "option1": "Male"
        },
        "cancer": {
          "label": "Malignancy",
          "option0": "No",
          "option1": "Yes"
        },
        "chronicHF": {
          "label": "Chronic Heart Failure",
          "option0": "No",
          "option1": "Yes"
        },
        "chronicLung": {
          "label": "Chronic Lung Disease",
          "option0": "No",
          "option1": "Yes"
        },
        "heartRate": {
          "label": "Heart Rate",
          "option0": "< 110 beats/min",
          "option1": "≥ 110 beats/min"
        },
        "bp": {
          "label": "Systolic Blood Pressure",
          "option0": "< 100 mmHg",
          "option1": "≥ 100 mmHg"
        },
        "respRate": {
          "label": "Respiratory Rate",
          "option0": "≤ 30 breaths/min",
          "option1": "> 30 breaths/min"
        },
        "temperature": {
          "label": "Temperature",
          "option0": "≥ 36 °C",
          "option1": "< 36 °C"
        },
        "mentalStatus": {
          "label": "Mental Status",
          "option0": "Normal",
          "option1": "Disorientation, lethargy, stupor, or coma"
        },
        "oxygen": {
          "label": "Oxygen Saturation",
          "option0": "≥ 90%",
          "option1": "< 90%"
        }
      },
      "result": {
        "class1": "Class I: Very Low Risk (0.0-1.6% 30-day mortality)",
        "class2": "Class II: Low Risk (1.7-3.5% 30-day mortality)",
        "class3": "Class III: Intermediate Risk (3.2-7.1% 30-day mortality)",
        "class4": "Class IV: High Risk (4.0-11.4% 30-day mortality)",
        "class5": "Class V: Very High Risk (10-24.5% 30-day mortality)"
      },
      "extraDescription": "Patients are stratified into five risk classes based on their total score: Very Low Risk (≤ 65 points); Low Risk (66-85 points); Intermediate Risk (86-105 points); High Risk (106-125 points); Very High Risk (> 125 points)."
    },
    "lee": {
      "name": "Revised Cardiac Risk Index (RCRI)",
      "description": "A clinical prediction rule used to estimate the risk of major cardiac complications after non-cardiac surgery.",
      "criteria": {
        "highRiskSurgery": {
          "label": "High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)",
          "option0": "No",
          "option1": "Yes"
        },
        "historyIschemicHeartDisease": {
          "label": "History of ischemic heart disease",
          "option0": "No",
          "option1": "Yes"
        },
        "historyCHF": {
          "label": "History of congestive heart failure",
          "option0": "No",
          "option1": "Yes"
        },
        "historyCerebrovascularDisease": {
          "label": "History of cerebrovascular disease",
          "option0": "No",
          "option1": "Yes"
        },
        "insulinTreatment": {
          "label": "Pre-operative treatment with insulin",
          "option0": "No",
          "option1": "Yes"
        },
        "creatinineOver2": {
          "label": "Pre-operative creatinine >2 mg/dL / 176.8 µmol/L",
          "option0": "No",
          "option1": "Yes"
        }
      },
      "result": {
        "class1": "0 points – Very Low Risk (~0.4% risk of major cardiac complications)",
        "class2": "1 point – Low Risk (~0.9% risk of major cardiac complications)",
        "class3": "2 points – Moderate Risk (~6.6% risk of major cardiac complications)",
        "class4": "3+ points – High Risk (>11% risk of major cardiac complications)"
      },
      "extraDescription": "Extra information:\n• For History of ischemic heart disease:\n  - History of myocardial infarction (MI)\n  - History of positive exercise test\n  - Current chest pain considered due to myocardial ischemia\n  - Use of nitrate therapy\n  - ECG with pathological Q waves\n• For History of congestive heart failure:\n  - Pulmonary edema\n  - Bilateral rales or S3 gallop\n  - Paroxysmal nocturnal dyspnea\n  - Chest x-ray (CXR) showing pulmonary vascular redistribution"
    },
    "caprini": {
      "name": "Caprini Score",
      "description": "The Caprini Score is a validated risk assessment tool to estimate the risk of venous thromboembolism (VTE) based on patient-specific risk factors.",
      "criteria": {
        "age": {
          "label": "Age, years",
          "option0": "≤40",
          "option1": "41–60",
          "option2": "61–74",
          "option3": "≥75"
        },
        "sex": {
          "label": "Sex",
          "male": "Male",
          "female": "Female"
        },
        "surgery": {
          "label": "Type of Surgery",
          "none": "None",
          "minor": "Minor (anesthesia <45 min)",
          "major": "Major (>45 min, laparoscopic/arthroscopic)",
          "arthroplasty": "Elective major arthroplasty or hip, pelvis, leg fracture"
        },
        "recentMajorSurgery": {
          "label": "Recent (<1 month) Major Surgery",
          "no": "No",
          "yes": "Yes"
        },
        "chf": {
          "label": "Congestive Heart Failure (CHF)",
          "no": "No",
          "yes": "Yes"
        },
        "sepsis": {
          "label": "Sepsis",
          "no": "No",
          "yes": "Yes"
        },
        "pneumonia": {
          "label": "Pneumonia",
          "no": "No",
          "yes": "Yes"
        },
        "plasterCast": {
          "label": "Immobilizing Plaster Cast",
          "no": "Not applied",
          "yes": "Applied"
        },
        "fracture": {
          "label": "Hip, Pelvis, or Leg Fracture",
          "no": "Absent",
          "yes": "Present"
        },
        "stroke": {
          "label": "Stroke",
          "no": "Absent",
          "yes": "Present"
        },
        "multipleTrauma": {
          "label": "Multiple Trauma",
          "no": "Absent",
          "yes": "Present"
        },
        "spinalInjury": {
          "label": "Acute Spinal Cord Injury Causing Paralysis",
          "no": "Absent",
          "yes": "Present"
        },
        "varicose": {
          "label": "Varicose Veins",
          "no": "Absent",
          "yes": "Present"
        },
        "swollenLegs": {
          "label": "Current Swollen Legs",
          "no": "Absent",
          "yes": "Present"
        },
        "centralAccess": {
          "label": "Current Central Venous Access",
          "no": "Absent",
          "yes": "Present"
        },
        "dvtPe": {
          "label": "History of DVT/PE",
          "no": "Absent",
          "yes": "Present"
        },
        "familyThrombosis": {
          "label": "Family History of Thrombosis",
          "no": "Absent",
          "yes": "Present"
        },
        "factorVLeiden": {
          "label": "Positive Factor V Leiden",
          "no": "Absent",
          "yes": "Present"
        },
        "prothrombin": {
          "label": "Positive Prothrombin 20210A",
          "no": "Absent",
          "yes": "Present"
        },
        "homocysteine": {
          "label": "Elevated Serum Homocysteine",
          "no": "Absent",
          "yes": "Present"
        },
        "lupusAnticoagulant": {
          "label": "Positive Lupus Anticoagulant",
          "no": "Absent",
          "yes": "Present"
        },
        "anticardiolipin": {
          "label": "Elevated Anticardiolipin Antibody",
          "no": "Absent",
          "yes": "Present"
        },
        "hit": {
          "label": "Heparin-induced Thrombocytopenia (HIT)",
          "no": "Absent",
          "yes": "Present"
        },
        "otherThrombophilia": {
          "label": "Other Congenital or Acquired Thrombophilia",
          "no": "Absent",
          "yes": "Present"
        },
        "mobility": {
          "label": "Mobility",
          "normal": "Normal, out of bed",
          "bedRest": "Medical patient on bed rest",
          "confined": "Patient confined to bed >72 hours"
        },
        "ibd": {
          "label": "History of Inflammatory Bowel Disease",
          "no": "No",
          "yes": "Yes"
        },
        "bmi": {
          "label": "BMI >25",
          "no": "No",
          "yes": "Yes"
        },
        "mi": {
          "label": "Acute Myocardial Infarction (MI)",
          "no": "No",
          "yes": "Yes"
        },
        "copd": {
          "label": "COPD",
          "no": "No",
          "yes": "Yes"
        },
        "malignancy": {
          "label": "Present or Previous Malignancy",
          "no": "No",
          "yes": "Yes"
        },
        "otherRiskFactors": {
          "label": "Other Risk Factors",
          "no": "No",
          "yes": "Yes"
        }
      },
      "result": {
        "lowest": "Lowest risk: Minimal risk. Prophylaxis: Early ambulation and mechanical prophylaxis during hospitalization.",
        "low": "Low risk: Consider mechanical prophylaxis.",
        "moderate": "Moderate risk: Mechanical prophylaxis ± pharmacologic prophylaxis.",
        "high": "High risk: Combined mechanical and pharmacologic prophylaxis for 7–10 days.",
        "high2": "Very high risk: Combined prophylaxis for 7–10 days.",
        "highest": "Highest risk: Combined prophylaxis for 30 days."
      },
      "extraDescription": "The Caprini Score is endorsed by the American Venous Forum and validated in surgical and hospitalized patients to guide VTE prophylaxis. It stratifies patients based on cumulative risk factors, helping tailor the duration and type of prophylaxis. Higher scores correlate with increased VTE incidence, particularly in cancer and orthopedic surgery patients. The score is especially valuable in perioperative planning and improving adherence to thromboprophylaxis protocols."    },
    "hasbled": {
      "name": "HAS-BLED Score",
      "description": "This score estimates the risk of major bleeding in patients on anticoagulation to guide management in atrial fibrillation care.",
      "criteria": {
        "hypertension": {
          "label": "Hypertension (systolic >160 mmHg)"
        },
        "renal": {
          "label": "Renal Disease (dialysis, transplant, or Cr >2.26 mg/dL)"
        },
        "liver": {
          "label": "Liver Disease (cirrhosis or bilirubin >2× normal with elevated enzymes)"
        },
        "stroke": {
          "label": "Stroke History"
        },
        "bleeding": {
          "label": "Prior Major Bleeding or Bleeding Predisposition"
        },
        "labileINR": {
          "label": "Labile INR (unstable/high, TTR <60%)"
        },
        "age": {
          "label": "Age >65 years"
        },
        "medication": {
          "label": "Medication Use Predisposing to Bleeding (aspirin, clopidogrel, NSAIDs)"
        },
        "alcohol": {
          "label": "Alcohol Use (≥8 drinks/week)"
        }
      },
      "result": {
        "lowest": "Relatively low risk of major bleeding (0.9%, 1.13 bleeds per 100 patients per year)",
        "low": "Relatively low risk of major bleeding 3.4% (1.02 bleeds per 100 patients per year)",
        "moderate": "Moderate risk of major bleeding (4.1%, 1.88 bleeds per 100 patients per year)",
        "high1": "High risk of major bleeding (5.8%, 3.72 bleeds per 100 patients per year)",
        "high2": "High risk of major bleeding (8.9%, 8.7 bleeds per 100 patients per year)",
        "high3": "High risk of major bleeding (9.1%, 12.5 bleeds per 100 patients per year)",
        "veryHigh": "Very high risk of major bleeding. Scores above 5 are too rare to determine risk, but are likely to exceed 10%"
      },
      "extraDescription": "The most important pitfall is using HAS-BLED as an absolute cut-off to withhold or withdraw anticoagulation. Keep in mind that in the vast majority of AF patients risk of stroke (and associated outcome) outweighs risk of bleeding. Instead, HAS-BLED should be used as an alarmbell which assists in minimizing the potential risk of bleeding by signaling risk factors that can be avoided or reversed."
    },
    "news2": {
      "name": "NEWS 2 Score",
      "description": "A score for assessing the severity of patients with acute respiratory syndromes and is aimed to a greater extent at assessing the current condition of the patient and to a lesser extent at assessing the prognosis of the disease",
      "criteria": {
        "respiratoryRate": {
          "label": "Respiratory Rate (breaths/min)",
          "option0": "12-20",
          "option1": "9-11",
          "option2": "21-24",
          "option3": "≤8 or ≥25"
        },
        "spo2": {
          "label": "SpO2 (%)",
          "option0": "≥96%",
          "option1": "94-95%",
          "option2": "92-93%",
          "option3": "≤91%"
        },
        "oxygenSupplementation": {
          "label": "Oxygen Supplementation",
          "option1": "Room air",
          "option2": "Supplemental oxygen"
        },
        "temperature": {
          "label": "Temperature (°C)",
          "option0": "36.1-38.0°C",
          "option1": "35.1-36.0°C or 38.1-39.0°C",
          "option2": "≥39.1°C",
          "option3": "≤35.0°C"
        },
        "systolicBP": {
          "label": "Systolic Blood Pressure (mmHg)",
          "option0": "111-219",
          "option1": "101-110",
          "option2": "91-100",
          "option3": "≤90 or ≥220"
        },
        "pulse": {
          "label": "Pulse (bpm)",
          "option0": "51-90",
          "option1": "41-50 or 91-110",
          "option2": "111-130",
          "option3": "≤40 or ≥131"
        },
        "consciousness": {
          "label": "Consciousness",
          "option1": "Alert",
          "option2": "New-onset confusion, disorientation, agitation, or unresponsive"
        }
      },
      "result": {
        "lowest": "Low risk: monitoring minimum every 12 hours.",
        "low": "Low risk: monitoring minimum every 4-6 hours.",
        "medium": "Medium risk: monitoring minimum every hour",
        "high": "High risk: continuous monitoring of vital signs"
      },
      "extraDescription": "Score of 3 in any individual parameter can be qualified as low-medium risk with recommended monitoring every hour"
    },
    "pgcs": {
      "name": "Pediatric Glasgow Coma Scale (pGCS)",
      "description": "The Pediatric Glasgow Coma Scale (pGCS) allows to obtain, track and communicate the mental status and level of consciousness for children (≤2 years of age)",
      "criteria": {
        "eye": {
          "label": "Eye Opening",
          "option1": "No response",
          "option2": "To pain only",
          "option3": "To verbal stimuli",
          "option4": "Spontaneously"
        },
        "verbal": {
          "label": "Verbal Response",
          "option1": "No response",
          "option2": "Moans in response to pain",
          "option3": "Cries in response to pain",
          "option4": "Irritable cries",
          "option5": "Coos and babbles"
        },
        "motor": {
          "label": "Motor Response",
          "option1": "No response",
          "option2": "Responds to pain with decerebrate posturing (abnormal extension)",
          "option3": "Responds to pain with decorticate posturing (abnormal flexion)",
          "option4": "Withdraws in response to pain",
          "option5": "Withdraws to touch",
          "option6": "Moves spontaneously and purposefully"
        }
      },
      "result": {
        "mild": "May indicate mild dysfunction, although a person with no neurologic disabilities would receive a GCS of 15",
        "moderate": "May indicate moderate dysfunction",
        "severe": "Is indicative of severe dysfunction"
      },
      "extraDescription": "Patients who are intubated are unable to speak, and their verbal score cannot be assessed. They are evaluated only based on eye opening and motor scores, and the suffix T is added to their score to indicate intubation. In intubated patients, the maximum GCS score is 10T and the minimum score is 2T."
    },
    "phoenix": {
      "name": "Phoenix Sepsis Score",
      "description": "A tool to assess life-threatening organ dysfunction due to infection in pediatric patients.",
      "extraDescription": "Score ≥2 + ≥1 cardiovascular point (Lactate, Vasoactive medications, MAP) suggests septic shock.",
      "criteria": {
        "respiratory": {
          "label": "Respiratory",
          "option0": "• PaO₂/FiO₂ ≥400\nor\n• SpO₂/FiO₂ ≥292",
          "option1": "• PaO₂/FiO₂ <400 on any respiratory support\nor\n• SpO₂/FiO₂ <292 on any respiratory support",
          "option2": "• PaO₂/FiO₂ 100-200 with IMV\nor\n• SpO₂/FiO₂ 148-220 with IMV",
          "option3": "• PaO₂/FiO₂ <100 with IMV\nor\n• SpO₂/FiO₂ <148 with IMV"
        },
        "coagulation_platelets": {
          "label": "Platelets (x10³/µL)",
          "option0": "≥100",
          "option1": "<100"
        },
        "coagulation_inr": {
          "label": "INR",
          "option0": "≤1.3",
          "option1": ">1.3"
        },
        "coagulation_d_dimer": {
          "label": "D-dimer",
          "option0": "≤2 μg/mL FEU",
          "option1": ">2 μg/mL FEU"
        },
        "coagulation_fibrinogen": {
          "label": "Fibrinogen",
          "option0": "≥100 mg/dL",
          "option1": "<100 mg/dL"
        },
        "neurological_gcs": {
          "label": "Glasgow Coma Score",
          "option0": "GCS >10; pupils reactive",
          "option1": "GCS ≤10",
          "option2": "Fixed pupils bilaterally"
        },
        "cardiovascular_lactate": {
          "label": "Lactate",
          "option0": "<5 mmol/L",
          "option1": "5-10.9 mmol/L",
          "option2": ">10.9 mmol/L"
        },
        "cardiovascular_med": {
          "label": "Vasoactive medications",
          "option0": "No vasoactive medications",
          "option1": "1 vasoactive medication",
          "option2": "2 and more vasoactive medications"
        },
        "cardiovascular_map": {
          "label": "Mean Arterial Pressure (MAP)",
          "option0": "<1 m: >30;\n1–11 m: >38;\n1-2 years: >43;\n2-5 years: >44;\n5-12 years: >48;\n12-17 years: >51",
          "option1": "<1 m: 17-30;\n1–11 m: 25–38;\n1-2 years: 31–43;\n2-5 years: 32–44;\n5-12 years: 36–48;\n12-17 years: 38–51",
          "option2": "<1 m: <17;\n1–11 m: <25;\n1-2 years: <31;\n2-5 years: <32;\n5-12 years: <36;\n12-17 years: <38"
        }
      },
      "result": {
        "noSepsis": "No sepsis",
        "sepsisSuspected": "Sepsis suspected (≥2 points)"
      }
    },
  "apgar": {
    "name": "Apgar Score",
    "description": "A quick test performed on a baby at 1 and 5 minutes after birth to determine physical condition",
    "extraDescription": "The 1-minute score determines how well the baby tolerated the birthing process.;The 5-minute score tells the health care provider how well the baby is doing outside the mother's womb.",
    "criteria": {
      "hr": {
        "label": "Pulse",
        "option0": "Absent",
        "option1": "< 100 beats per minute",
        "option2": "≥ 100 beats per minute"
      },
      "lung": {
        "label": "Breathing effort",
        "option0": "Not breathing",
        "option1": "Respirations are slow or irregular",
        "option2": "Regular breathing"
      },
      "muscle": {
        "label": "Muscle tone",
        "option0": "Muscles are loose and floppy",
        "option1": "Some muscle tone (flexion)",
        "option2": "Flexed arms and legs that resist extension"
      },
      "skin": {
        "label": "Skin color",
        "option0": "Totally blue",
        "option1": "Pink and the extremities are blue (acrocyanosis)",
        "option2": "No cyanosis body and extremities pink"
      },
      "reflex": {
        "label": "Reflex response to irritable stimuli",
        "option0": "No response to stimulation",
        "option1": "Grimacing",
        "option2": "Grimacing and a cough, sneeze, or vigorous cry"
      }
    },
    "result": {
      "distress": "Distress",
      "normal": "Normal"
    }
  },
    "qsofa" : {
      "name": "qSofa Score",
      "description": "Tool used to identify patients with suspected infection who are at greater risk for poor outcomes, such as increased mortality or prolonged intensive care unit (ICU) stays. It is designed for rapid assessment without the need for laboratory tests, making it particularly useful in urgent and resource-limited settings.",
      "criteria": {
        "mental": {
          "label": "A Glasgow Coma Scale (GCS) score less than 15"
        },
        "respiratory": {
          "label": "Respiratory rate of 22 breaths per minute or greater"
        },
        "sysBp": {
          "label": "Systolic blood pressure (SBP) of 100 mmHg or less"
        }
      },
      "result": {
        "notHighRisk": "A qSOFA score ≤ 1 suggests a lower risk of poor outcome; continue clinical assessment and monitoring.",
        "highRisk": "A qSOFA score ≥2 suggests a high risk of poor outcome; consider further evaluation for sepsis and escalation of care."
      },
      "extraDescription": "qSOFA was introduced as part of the Sepsis-3 definition in 2016 to provide a quick bedside assessment tool that does not require laboratory data. Unlike the full SOFA score, qSOFA can be calculated outside the ICU, such as in emergency departments or general wards, helping clinicians promptly identify patients who may require escalation of care. While it is a rapid screening tool, it does not replace clinical judgment or more comprehensive diagnostic assessments."
    }
  },
  "CalculatorsPage": {
    "metaTitleDefault": "Calculator",
    "metaDescDefault": "Calculator page",
    "calculate": "Calculate",
    "result": "Calculated Results:",
    "alert": "This calculator is for double-checking dosage and should NOT be used as the sole reference.",
    "not_found": "Config not found",
    "weight": "Weight",
    "height": "Height",
    "age": "Age",
    "sex": "Sex",
    "male": "Male",
    "female": "Female",
    "activity": "Activity Level",
    "dose": "Dose",
    "bolus": "Bolus",
    "induction": "Induction of general anesthesia",
    "infusion": "Infusion",
    "maintenanceDose": "Maintenance Dose",
    "total": "Total",
    "dosePerKg": "Dose Per Kg",
    "inductionDose": "Induction Dose",
    "infusionDosePerKg": "Infusion Dose Per Kg",
    "iv": "IV",
    "im": "IM",
    "inductionMCG": "Induction MCG",
    "inductionML": "Induction ML",
    "drugVolume": "Drug Volume",
    "drugAmount": "Drug Amount",
    "ivPerMin": "IV Per Min",
    "ivPerHr": "IV Per Hr",
    "totalVolume": "Total Volume after dilute",
    "drugAmountInMl": "Drug Concentration in mL",
    "drugConcentration": "Drug Concentration",
    "tivaAnestesiaDepth": "TIVA - anesthesia depth",
    "tivaDosePerHr": "TIVA - IV per hour",
    "concentration": "Concentration",
    "solutionVolume": "Solution Volume",
    "substanceAmount": "Substance Amount",
    "unit": "Unit of measurement",
    "sysBP": "Systolic Blood Pressure",
    "diaBP": "Diastolic Blood Pressure",
    "currentPotassiumLvl": "Current Potassium Level",
    "potassiumChlorideSol": "Potassium Chloride Solution Concentration",
    "bicarbonateLevel": "Current Bicarbonate Level",
    "stockConcentration": "Stock Concentration",
    "desiredConcentration": "Desired Concentration",
    "finalVolume": "Final Volume",
    "stockSolutionVolume": "Volume of Stock Solution",
    "diluentVolume": "Volume of Diluent",
    "creatinine": "Serum Creatinine",
    "heartRate": "Heart Rate",
    "systolicBP": "Systolic Blood Pressure",
    "urineAmount" : "Urine amount",
    "period": "Period",
    "hematocrit": "Hematocrit",
    "removedPercentage": "Removal Percentage for RPV",
    "sodiumLevel": "Current Sodium Level",
    "albuminLevel": "Current Albumin Level",
    "chlorideLevel": "Current Chloride Level",
    "oralSedation": "Oral Sedation Dose",
    "imSedation": "IM Sedation Dose",
    "ivSedation": "IV Sedation Dose",
    "intranasal": "Intranasal Dose",
    "eplilepticBolus": "Status Epilepticus Bolus Dose",
    "eplilepticInfusion": "Status Epilepticus Infusion per min",
    "imPremed": "IM Premedication Dose",
    "ivInduction": "IV Induction Dose",
    "unit_mg": "mg",
    "unit_g": "g",
    "unit_mcg": "mcg",
    "unit_mg_kg": "mg/kg",
    "unit_mcg_kg": "mcg/kg",
    "unit_m": "m",
    "unit_cm": "cm",
    "unit_ml": "ml",
    "unit_l": "l",
    "unit_months": "months",
    "unit_years": "years",
    "volume_20": "20 ml",
    "volume_10": "10 ml",
    "volume_50": "50 ml",
    "volume_100": "100 ml",
    "volume_200": "200 ml",
    "": "",

    "actilyse": {
      "label": "Actilyse (Alteplase) Calculator",
      "bolus": "Bolus Dose (IV over 1 min)",
      "infusion": "Infusion Dose (IV over 60 mins)",
      "annotation": "Alteplase (brand name: Actilyse) is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent to dissolve blood clots in various medical conditions.\n\nIndications:\n- Acute Ischemic Stroke: Administered to improve functional outcomes by dissolving clots obstructing cerebral blood flow.\n- Acute Massive Pulmonary Embolism: Employed to lyse clots in the pulmonary arteries, especially in cases with hemodynamic instability.\n- Blocked Catheters: Applied in small doses to clear occlusions in central venous catheters.\n\nDosage and Administration:\n- Acute Ischemic Stroke: The recommended total dose is 0.9 mg/kg (maximum 90 mg). Administer 10% of the total dose as an initial intravenous bolus over 1 minute, followed by the remaining 90% as a continuous infusion over 60 minutes.\n- Pulmonary Embolism: Typically, 100 mg is administered over 2 hours; however, lower doses (e.g., 0.6 mg/kg) have been studied to reduce bleeding risks.\n- Blocked Catheters: Instill 2 mg/2 mL into the occluded catheter; if function is not restored within 120 minutes, a second dose may be administered.\n\nContraindications:\n- Active internal bleeding\n- Recent intracranial or intraspinal surgery or trauma\n- Severe uncontrolled hypertension\n- Known bleeding diathesis\n- Current use of oral anticoagulants with an elevated INR\n\nWarnings and Precautions:\n- Bleeding Risk: Monitor patients for signs of bleeding, including intracranial hemorrhage. Use caution in patients with recent major surgery, gastrointestinal bleeding, or other conditions that may increase bleeding risk.\n- Angioedema: Be vigilant for signs of orolingual angioedema, especially in patients on concomitant ACE inhibitors.\n- Cholesterol Embolization: Rarely, systemic embolization of cholesterol may occur.\n\nMonitoring:\n- Neurological Assessments: Frequently monitor for any signs of neurological deterioration.\n- Blood Pressure: Maintain blood pressure within recommended limits before, during, and after administration.\n- Laboratory Tests: Obtain baseline coagulation parameters and monitor as clinically indicated.\n\nNote: The use of alteplase should adhere strictly to established guidelines and protocols, considering the specific clinical scenario and patient characteristics."
    },

    "bmi": {
      "label": "Body Mass Index",
      "bmi": "BMI",
      "annotation": "BMI reference ranges are based on WHO guidelines: \n- under 18.5 (underweight) \n- 18.5–24.9 (normal) \n- 25–29.9 (overweight) \n- ≥30 (obese)."
    },

    "dailyCalories": {
      "label": "Daily Calorie Requirements",
      "sedentary": "Sedentary",
      "lightActivity": "Light Activity",
      "moderateActivity": "Moderate Activity",
      "veryActive": "Very Active",
      "superActive": "Super Active",
      "bmr": "Basal Metabolic Rate",
      "tdee": "Total Daily Energy Expenditure",
      "annotation": "This calculation uses the Mifflin-St Jeor formula. Actual calorie needs may vary by individual."
    },

    "creatinineClearance": {
      "label": "Creatinine Clearance",
      "clearance": "Creatinine Clearance",
      "annotation": "Uses the Cockcroft-Gault formula to estimate creatinine clearance\nStage I: Kidney damage with normal or increased GFR ≥90 mL/min/1.73 m²\nStage II: Kidney damage with mild decrease in GFR (60–89 mL/min/1.73 m²)\nStage III: Moderate decrease in GFR (30–59 mL/min/1.73 m²)\nStage IV: Severe decrease in GFR (15–29 mL/min/1.73 m²)\nStage V: Kidney failure (GFR <15 mL/min/1.73 m²)"    },

    "dailyWaterBalance": {
      "label": "Daily Water Balance",
      "waterIntake": "Water Intake",
      "foodIntake": "Food Intake",
      "infusionIntake": "Infusion Intake",
      "urineOutput": "Urine Output",
      "fecesOutput": "Feces Output",
      "extraOutput": "Other Losses",
      "weight": "Weight",
      "hyperthermia": "Hyperthermia",
      "mechanicalVentilation": "Mechanical Ventilation",
      "balance": "Daily water balance taking into account perspiration",
      "annotation": "This provides a rough estimate of water balance based on intake and output. Clinical context may require adjustments."
    },

    "algoverIndex": {
      "label": "Algover Index",
      "index": "Algover Index",
      "annotation": "Algover index helps estimate hypovolemia risk; values above 1.0 may indicate significant volume depletion."
    },
    "dailyDiuresis": {
      "label": "Hourly Diuresis Rate",
      "absoluteDiuresis": "Absolute hourly Diuresis Rate",
      "hourlyDiuresis": "Hourly Diuresis Rate",
      "annotation": "The following values \u200B\u200Bare usually used as a guide (in ml/kg/h):\nAdults: the norm is considered to be ≈0.5–1 ml/kg/h (some sources give up to 2 ml/kg/h, everything depends on specific clinical conditions).\nChildren: the indicator is higher and strongly depends on age (in newborns it can reach 2–3 ml/kg/h, in older children it is closer to the indicators of adults)."
    },
    "plasmaExchange": {
      "label": "Plasma Exchange Calculator",
      "totalBloodVolume": "Total Blood Volume",
      "plasmaVolume": "Circulating Plasma Volume",
      "removedPlasmaVolume": "Removed Plasma Volume",
      "annotation": "Formulas used in this calculator:\n1. Total Blood Volume (TBV) = Weight (kg) × Coefficient, where the coefficient is 70 mL/kg for males and 65 mL/kg for females.\n2. Circulating Plasma Volume (PV) = TBV × ((100 - Hematocrit) / 100).\n3. Removed Plasma Volume (RPV) = PV × (Removal Percentage / 100) × Correction Factor.\n\nThe Correction Factor is fixed at 1.05 by default and adjusts the removal volume based on clinical requirements."
    },
    "thiopental": {
      "label": "Thiopental",
      "recDosage": "IV dose 3–5 mg/kg",
      "annotation": "Thiopental is a rapid-onset, short-acting barbiturate used primarily for the induction of anesthesia and for short surgical procedures. It is also utilized in the management of status epilepticus and for reducing intracranial pressure.\n\nConcentration and Preparation:\n- Available as a freeze-dried powder: 500 mg in 10 mL or 1 g in 20 mL vials.\n- Typically reconstituted to a 2.5% solution (25 mg/mL) using sterile water or saline. For continuous IV infusion, concentrations of 0.2% or 0.4% are used. \n\nDosage Considerations:\n- Adult IV induction: 3–5 mg/kg administered over 20–40 seconds. \n- Pediatric IV induction: 2–7 mg/kg based on age and clinical status. \n\nOnset and Duration:\n- Onset: 30–40 seconds after IV administration. \n- Duration: 5–10 minutes. \n\nWarnings and Precautions:\n- Respiratory Depression: Risk of apnea and respiratory depression; ensure resuscitative equipment is available. \n- Cardiovascular Effects: May cause hypotension, especially in hypovolemic or hypertensive patients. \n- Contraindications: Severe cardiovascular disease, porphyria, hypersensitivity to barbiturates. \n- Use in Specific Populations: Caution in patients with hepatic or renal impairment, asthma, myasthenia gravis, or severe anemia. \n\nMonitoring:\n- Continuous monitoring of respiratory and cardiovascular status during administration. \n- Observe for signs of over-sedation or adverse reactions."
    },
    "propofol": {
      "label": "Propofol",
      "recDosage": "IV dose 1–2.5 mg/kg",
      "annotation": "Propofol is a short-acting intravenous anesthetic agent used for the induction and maintenance of general anesthesia, as well as for sedation in various medical procedures. It is known for its rapid onset and quick recovery profile.\n\n20 ml = 200 mg emulsion\n\nIndications:\n• Induction of general anesthesia\n• Maintenance of general anesthesia\n• Sedation for mechanically ventilated patients in the Intensive Care Unit (ICU)\n• Monitored Anesthesia Care (MAC) sedation for procedures\n\nDosage Considerations:\n• Adult Induction of Anesthesia:\n  - Healthy adults <65 years: 2 to 2.5 mg/kg IV bolus\n  - Elderly, debilitated, or ASA-PS III/IV patients: Reduce dose; typically 1 to 1.5 mg/kg IV bolus\n• Adult Maintenance of Anesthesia:\n  - Continuous infusion: 100 to 200 mcg/kg/min (6 to 12 mg/kg/hr)\n  - Adjust infusion rate based on patient response and surgical conditions\n• Adult Sedation in ICU:\n  - Initiate at 5 mcg/kg/min (0.3 mg/kg/hr) IV infusion\n  - Titrate by 5 to 10 mcg/kg/min (0.3 to 0.6 mg/kg/hr) every 5 to 10 minutes to achieve desired sedation level\n  - Maintenance infusion: Typically 5 to 50 mcg/kg/min (0.3 to 3 mg/kg/hr)\n• Pediatric Induction of Anesthesia (≥2 months):\n  - 2.5 to 3.5 mg/kg IV bolus\n• Pediatric Maintenance of Anesthesia:\n  - Continuous infusion: 125 to 300 mcg/kg/min (7.5 to 18 mg/kg/hr)\n  - Following the first 30 minutes, infusion rates may be reduced\n\nWarnings:\n• Risk of hypotension and respiratory depression, especially with rapid administration or high doses\n• Use caution in patients with cardiac, respiratory, renal, or hepatic impairment\n• Not recommended for sedation in pediatric ICU patients due to risk of Propofol Infusion Syndrome\n• Strict aseptic technique required to prevent microbial contamination\n\nMonitoring:\n• Continuous monitoring of respiratory and cardiovascular status\n• Observe for signs of hypotension, apnea, or airway obstruction\n• Regular assessment of sedation levels and adjust dosage accordingly\n\nNote: Dosages should be individualized based on patient factors, procedure requirements, and clinical response. Always consult current clinical guidelines and institutional protocols.",
      "tiva": {
        "sedation": "Sedation",
        "lightPain": "Light pain",
        "laryngealMask": "Laryngeal mask",
        "moderatePain": "Moderate pain",
        "intubation": "Intubation",
        "strongPain": "Strong pain",
        "deep": "Deep anesthesia"
      }
    },
    "ketamine": {
      "label": "Ketamine",
      "recDosage": "IV dose 1.5–4.5 mg/kg",
      "annotation": "Ketamine is a dissociative anesthetic used for induction and maintenance of anesthesia and pain management. It is particularly useful in hypotensive patients due to its cardiovascular stimulant properties.\n\n2 mL = 100 mg.\n\nIndications:\n- Induction and maintenance of anesthesia\n- Pain management, including in opioid-tolerant patients\n- Treatment of refractory status epilepticus\n\nDosage Considerations:\n- Adult IV induction: 1 to 4.5 mg/kg IV; 2 mg/kg typically produces 5 to 10 minutes of surgical anesthesia within 30 seconds\n- Adult IM induction: 6.5 to 13 mg/kg IM; 9 to 13 mg/kg typically produces 12 to 25 minutes of surgical anesthesia within 3 to 4 minutes\n- Pediatric IV induction: 1 to 2 mg/kg IV over 60 seconds\n- Pediatric IM induction: 4 to 5 mg/kg IM\n- Pain management (adults): 0.3 mg/kg IV slow push; may repeat 0.15 mg/kg after 5 minutes; maximum cumulative dose 0.6 mg/kg in 45 minutes\n\nWarnings:\n- May cause transient increases in blood pressure, heart rate, and cardiac output; use with caution in patients with cardiovascular disease\n- Risk of emergence reactions, including vivid dreams, hallucinations, and delirium; pretreatment with a benzodiazepine may reduce incidence\n- Potential for respiratory depression, especially with rapid IV administration or high doses\n- Use with caution in patients with elevated intracranial or intraocular pressure\n- May increase muscle tone, making it unsuitable for procedures requiring muscle relaxation\n\nMonitoring:\n- Continuous monitoring of vital signs, including blood pressure, heart rate, and respiratory function\n- Observe for signs of emergence reactions during recovery\n- Monitor for potential adverse psychiatric effects, particularly in patients with a history of mental health disorders"
    },
    "gomh": {
      "label": "Sodium Oxybutyrate",
      "recDosage": "IV dose 50–150 mg/kg",
      "annotation": "1 mL = 200 mg. Typical intravenous (IV) dose ranges from 50 to 150 mg/kg. Onset of action is approximately 5–10 minutes, with a duration of 20–60+ minutes.\n\nNote: While sodium oxybate (the sodium salt of gamma-hydroxybutyric acid, or GHB) has been used historically as an anesthetic agent in some countries, its use in modern anesthesiology and intensive care units (ICUs) is limited. This is due to its potential for abuse, dependence, and the availability of safer alternatives. \n\nIn the United States, sodium oxybate is primarily approved for the treatment of narcolepsy with cataplexy and excessive daytime sleepiness. Its use is restricted under a Risk Evaluation and Mitigation Strategy (REMS) program to mitigate risks of abuse and serious adverse effects. Therefore, the application of sodium oxybate in anesthesiology and ICU settings should be approached with caution, considering current clinical guidelines and regulatory restrictions."
    },
    "fentanyl": {
      "label": "Fentanyl",
      "recDosage": "IV dose 0.5–2 mcg/kg",
      "annotation": "Fentanyl is a potent synthetic opioid analgesic used for pain management and as an adjunct to anesthesia. It is approximately 100 times more potent than morphine.\n\n2 ml = 0,05 mg (50 mcg) \n\nIndications:\n- Adjunct to general anesthesia\n- Management of acute and chronic pain\n\nDosage Considerations:\n- IV bolus: 0.5–2 mcg/kg\n- Continuous IV infusion: 0.5–3 mcg/kg/min\n- Transdermal patch: 12–100 mcg/hr, replaced every 72 hours\n\nWarnings:\n- Risk of respiratory depression, especially with concomitant use of CNS depressants\n- Potential for misuse, addiction, and dependence\n- Use caution in patients with hepatic or renal impairment\n- Contraindicated in patients with severe respiratory conditions or those who have used MAO inhibitors within the past 14 days\n\nMonitoring:\n- Continuous monitoring of respiratory and cardiovascular status during administration\n- Observe for signs of hypotension, bradycardia, and hypoventilation\n- Monitor for signs of misuse, abuse, or addiction"
    },
    "ditilin": {
      "label": "Ditilin (Succinylcholine)",
      "recDosage": "IV dose 0.6–1.5 mg/kg",
      "annotation": "Ditilin, also known as suxamethonium or succinylcholine, is a depolarizing neuromuscular blocker used to induce rapid muscle relaxation for procedures such as tracheal intubation and electroconvulsive therapy.\n\nPresentation:\n• 5 mL ampoule containing 100 mg (20 mg/mL).\n\nDosage Considerations:\n• Adults:\n  - Intravenous (IV) bolus: 0.6–1.5 mg/kg for rapid muscle relaxation.\n  - Intramuscular (IM): 3–4 mg/kg if IV access is not available; maximum 150 mg.\n• Pediatrics:\n  - IV bolus: 1–2 mg/kg.\n  - IM: 2–3 mg/kg; maximum 150 mg.\n\nPharmacokinetics:\n• Onset:\n  - IV: Approximately 30–60 seconds.\n  - IM: Approximately 2–3 minutes.\n• Duration:\n  - IV: 5–10 minutes.\n  - IM: 10–30 minutes.\n\nWarnings and Precautions:\n• Contraindications:\n  - Personal or familial history of malignant hyperthermia.\n  - Known hypersensitivity to succinylcholine.\n  - Conditions with upregulated acetylcholine receptors (e.g., recent burns, trauma, denervation injuries) due to risk of severe hyperkalemia.\n• Cautions:\n  - May cause bradycardia, especially in children or with repeated dosing; consider premedication with atropine.\n  - Risk of increased intraocular, intracranial, and intragastric pressure.\n  - Potential for triggering malignant hyperthermia; ensure appropriate monitoring and emergency measures are available.\n\nAdverse Effects:\n• Common: Muscle fasciculations, postoperative myalgia.\n• Serious: Hyperkalemia, malignant hyperthermia, arrhythmias, prolonged apnea due to pseudocholinesterase deficiency.\n\nMonitoring:\n• Continuous monitoring of neuromuscular function, respiratory status, and cardiovascular parameters is essential during administration.\n\nPrecurarization:\n• To reduce the incidence and severity of muscle fasciculations and postoperative myalgia associated with succinylcholine, a small dose of a non-depolarizing neuromuscular blocking agent (e.g., rocuronium 0.04 mg/kg) may be administered 2–3 minutes prior to succinylcholine. This technique, known as precurarization, has been shown to mitigate these side effects effectively. However, clinicians should be cautious of potential adverse effects, such as muscle weakness or difficulty swallowing, associated with the precurarizing agent."
    },
    "atracurium": {
      "label": "Atracurium",
      "recDosage": "IV dose 0.5–0.6 mg/kg",
      "annotation": "Atracurium is a non-depolarizing neuromuscular blocking agent used to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.\n\nConcentrations Available:\n- 2.5 mL = 25 mg\n- 5 mL = 50 mg\n\nDosage Considerations:\n- Initial Bolus: 0.4–0.5 mg/kg IV bolus\n- Onset: Approximately 2–3 minutes\n- Duration: Approximately 20–35 minutes\n- Maintenance: Continuous infusion of 5–10 mcg/kg/min may be used to maintain neuromuscular blockade\n\nWarnings and Precautions:\n- Histamine Release: Rapid administration may cause histamine release, leading to hypotension or bronchospasm; administer slowly to minimize risk.\n- Neuromuscular Diseases: Use with caution in patients with neuromuscular diseases (e.g., myasthenia gravis) as they may exhibit increased sensitivity.\n- Electrolyte Imbalances: Correct significant electrolyte imbalances before administration, as they may potentiate or antagonize neuromuscular blockade.\n\nMonitoring:\n- Neuromuscular Function: Utilize a peripheral nerve stimulator to monitor the degree of neuromuscular blockade and adjust dosage accordingly.\n- Vital Signs: Continuously monitor respiratory and cardiovascular status during administration and recovery.\n\nReversal of Neuromuscular Blockade:\n- Agents: Acetylcholinesterase inhibitors (e.g., neostigmine) in combination with anticholinergic agents (e.g., glycopyrrolate) can be used to reverse atracurium-induced neuromuscular blockade.\n- Sugammadex: Not effective for reversing atracurium; it is specific for aminosteroid neuromuscular blocking agents like rocuronium and vecuronium."
    },
    "dexon": {
      "label": "Dexamethasone",
      "recDosage": "IV dose 0.5–9 mg/kg/day",
      "annotation": "Dexamethasone is a potent synthetic corticosteroid used to reduce inflammation and suppress the immune system in various medical conditions.\n\nConcentration:\n• 1 mL = 4 mg dexamethasone sodium phosphate\n\nIndications:\n• Anti-inflammatory and immunosuppressive therapy:\n  - Management of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and severe allergies\n• Cerebral edema:\n  - Treatment of cerebral edema associated with brain tumors or head injury\n• Acute exacerbations of multiple sclerosis:\n  - Management of acute episodes in multiple sclerosis patients\n• Chemotherapy-induced nausea and vomiting:\n  - Prevention and treatment of nausea and vomiting associated with chemotherapy\n\nDosage Considerations:\n• Anti-inflammatory and immunosuppressive therapy:\n  - Initial dose: 0.5 to 9 mg/day IV/IM, divided every 12 hours, depending on the specific condition and patient response\n• Cerebral edema:\n  - Initial dose: 10 mg IV once, followed by 4 mg IM every 6 hours until symptoms subside; taper gradually over 5 to 7 days\n• Acute exacerbations of multiple sclerosis:\n  - 30 mg orally once daily for 1 week, followed by 4 to 8 mg orally every other day for 1 month\n• Chemotherapy-induced nausea and vomiting:\n  - Highly emetogenic chemotherapy: 12 to 20 mg orally/IV prior to chemotherapy, followed by 8 mg orally/IV once or twice daily for 2 to 4 days\n  - Moderately emetogenic chemotherapy: 8 mg orally/IV prior to chemotherapy, followed by 4 to 8 mg orally/IV on days 2 and 3\n\nWarnings:\n• Immunosuppression:\n  - Increased susceptibility to infections; avoid exposure to chickenpox or measles\n• Endocrine effects:\n  - May cause adrenal suppression; gradual dose reduction is recommended to discontinue therapy\n• Gastrointestinal effects:\n  - Risk of peptic ulcers; use with caution in patients with a history of ulcers\n• Cardiovascular effects:\n  - May cause hypertension and fluid retention; monitor patients with cardiovascular conditions\n• Ophthalmic effects:\n  - Prolonged use may result in cataracts, glaucoma, and ocular infections\n\nMonitoring:\n• Regular monitoring of blood pressure, blood glucose levels, and electrolytes\n• Watch for signs of infection or gastrointestinal bleeding\n• Periodic eye examinations during prolonged therapy\n\nNote:\n• Dosage should be individualized based on the specific condition, severity, and patient response\n• Use the lowest effective dose for the shortest duration possible to minimize potential adverse effects\n• Consult prescribing information and clinical guidelines for detailed dosing and administration recommendations"
    },
    "naloxone": {
      "label": "Naloxone",
      "recDosage": "IV dose 1.5–3 mcg/kg",
      "annotation": "Naloxone is an opioid antagonist used to reverse the effects of opioid overdose, including respiratory depression, sedation, and hypotension.\n\n1 mL = 0.4 mg (400mcg).\n\nIndications:\n• Emergency treatment of known or suspected opioid overdose\n• Reversal of opioid-induced respiratory and central nervous system depression\n• Adjunctive agent to increase blood pressure in septic shock\n\nDosage Considerations:\n• Adults:\n  - Opioid Overdose: Initial dose of 0.4 mg to 2 mg IV; if desired response is not obtained, doses may be repeated every 2 to 3 minutes. If no response is observed with a total dose of 10 mg, the diagnosis of opioid-induced toxicity should be questioned. Alternatively, may administer IM or subcutaneously.\n  - Reversal of Opioid Sedation: Initial dose of 0.1 to 0.2 mg IV at 2 to 3 minute intervals to the desired degree of reversal.\n• Pediatrics:\n  - Neonates: Initial dose of 0.01 mg/kg IV, IM, or subcutaneously; repeat every 2 to 3 minutes as needed.\n  - Children: Initial dose of 0.01 mg/kg IV; if desired response is not obtained, may give 0.1 mg/kg IV. If IV route is not available, may administer IM or subcutaneously in divided doses.\n\nWarnings:\n• May precipitate acute withdrawal symptoms in opioid-dependent patients, including neonates.\n• Use with caution in patients with cardiovascular disease or those receiving cardiotoxic drugs, as abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects.\n• The duration of action of some opioids may exceed that of naloxone; therefore, repeated doses or continuous infusion may be necessary.\n\nMonitoring:\n• Patients should be observed constantly until emergency care arrives and monitored for another 2 hours after the last dose of naloxone to ensure that breathing does not slow or stop.\n• Monitor for signs of recurrent respiratory depression, hypotension, ventricular tachycardia, fibrillation, and pulmonary edema."
    },
    "noradrenaline": {
      "label": "Noradrenaline (Norepinephrine)",
      "drug_var1": "4 ml",
      "drug_var2": "8 ml",
      "recDosage": "0.01–0.5 mcg/kg/min",
      "annotation": "Norepinephrine, also known as noradrenaline, is a potent vasopressor primarily used to manage severe hypotension and shock by stimulating α-adrenergic receptors, leading to vasoconstriction and increased blood pressure.\n\n4 mL ampule = 8 mg or 8 mL ampule = 16 mg.\n\nIndications:\n- Acute hypotension\n- Septic shock\n- Cardiogenic shock\n\nDosage Considerations:\n- Initial IV infusion: 8 to 12 mcg/min, titrated based on patient response.\n- Maintenance IV infusion: Typically 2 to 4 mcg/min.\n- High-dose therapy: Doses exceeding 0.5 mcg/kg/min may be associated with increased mortality and are generally reserved for refractory shock cases. \n\nWarnings:\n- Tissue ischemia: Risk of peripheral and visceral ischemia due to potent vasoconstriction; ensure adequate blood volume before administration. \n- Extravasation: Can cause local tissue necrosis; infuse through a large vein and monitor the infusion site closely. \n- Arrhythmias: Potential to induce cardiac arrhythmias; monitor cardiac function during infusion. \n\nMonitoring:\n- Continuous blood pressure monitoring until desired blood pressure is achieved, then every five minutes for the duration of the infusion. \n- Regular assessment of infusion site for signs of extravasation.\n- Continuous cardiac monitoring for arrhythmias."
    },
    "dopamine": {
      "label": "Dopamine",
      "drug_var1": "40 mg",
      "drug_var2": "5 mg",
      "recDosage": "0.5–20 mcg/kg/min",
      "annotation": "Dopamine it is a dopamine receptor agonist and is their endogenous ligand, used to improve hemodynamic status in patients with distributive shock or shock due to reduced cardiac output.\n\n5 mL = 200 mg (40 mg/mL) concentrate.\n\nIndications:\n- Treatment of shock due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation.\n\nDosage Considerations:\n- Low infusion rate (0.5-2 mcg/kg/min): Primarily stimulates dopaminergic receptors, leading to renal and mesenteric vasodilation.\n- Intermediate infusion rate (2-10 mcg/kg/min): Stimulates beta1-adrenergic receptors, enhancing myocardial contractility and cardiac output.\n- High infusion rate (10-20 mcg/kg/min): Stimulates alpha-adrenergic receptors, resulting in vasoconstriction and increased blood pressure.\n\nWarnings:\n- May cause tachycardia, arrhythmias, or excessive vasoconstriction at high doses.\n- Use with caution in patients with occlusive vascular diseases.\n- Correct hypovolemia before initiating dopamine therapy.\n\nMonitoring:\n- Continuous monitoring of cardiac function, blood pressure, and urine output is essential during dopamine infusion.\n- Regular assessment of the infusion site to prevent local ischemia or necrosis."
    },
    "nitroglycerin": {
      "label": "Nitroglycerin",
      "drug_var1": "10 mg/ml",
      "drug_var2": "5 mg/ml",
      "recDosage": "0.1-3 mcg/kg/min",
      "annotation": "Nitroglycerin is a potent vasodilator primarily used in the management of angina pectoris, acute myocardial infarction, and perioperative hypertension. It works by relaxing vascular smooth muscle, leading to vasodilation and reduced myocardial oxygen demand.\n\nConcentrations and Preparations:\n- Intravenous (IV) Solution: Available in concentrations such as 5 mg/mL or 10mg/mL, which can be diluted to desired concentrations for infusion.\n- Sublingual Tablets: Commonly available in doses of 0.3 mg, 0.4 mg, and 0.6 mg.\n- Transdermal Ointment: Typically a 2% formulation.\n\nIndications:\n- Management of angina pectoris\n- Acute myocardial infarction\n- Perioperative hypertension control\n- Acute heart failure\n\nDosage Considerations:\n- IV Infusion: Start at 0.1 mcg/kg/min and titrate up to 3 mcg/kg/min. Continuous monitoring of blood pressure and heart rate is essential.\n- Sublingual Administration: 0.3-0.6 mg every 5 minutes as needed for chest pain, up to 3 doses in 15 minutes. If pain persists after three doses, seek emergency medical attention. \n- Transdermal Ointment: Apply 1-2 inches of 2% nitroglycerin ointment on a non-hairy area of the upper body. Onset of activity is 3-5 minutes, with a duration of action of approximately 8 hours. \n\nWarnings:\n- May cause severe hypotension; monitor blood pressure closely.\n- Contraindicated in patients using phosphodiesterase inhibitors (e.g., sildenafil) within the past 24-48 hours due to the risk of profound hypotension.\n- Use with caution in patients with hypovolemia or severe anemia.\n- May cause reflex tachycardia; consider co-administration with beta-blockers if appropriate.\n\nMonitoring:\n- Continuous blood pressure and heart rate monitoring during IV administration.\n- Watch for signs of hypotension, tachycardia, or headache.\n- Assess for tolerance development with prolonged use; a nitrate-free interval may be necessary to prevent tolerance."
    },
    "sufentanil": {
      "label": "Sufentanil",
      "recDosage": "1-2 mcg/kg - IV induction dose ",
      "annotation": "Sufentanil is a potent synthetic opioid analgesic used in anesthesia for its rapid onset and short duration of action. It is primarily utilized for induction and maintenance of anesthesia, as well as for postoperative pain management.\n\n 5 mL = 250 mcg (50 mcg/mL).\n\n Indications:\n  • Induction and maintenance of anesthesia\n  • Supplement to balanced anesthesia\n  • Postoperative analgesia\n\n Dosage Considerations:\n  • Adult IV induction:\n    - Low-dose: 0.1-2 mcg/kg, THEN 10-50 mcg IV PRN\n    - High-dose: 8-30 mcg/kg (as sole anesthetic agent), THEN 25-30 mcg IV PRN\n  • Adult IV maintenance:\n    - Continuous infusion: 0.5-1.5 mcg/kg/hr\n  • Pediatric IV induction:\n    - 0.2-0.5 mcg/kg, often combined with other anesthetic agents\n\n Onset and Duration:\n  • IV administration:\n    - Onset: Rapid, within 1-3 minutes\n    - Duration: Dose-dependent; typically 20-45 minutes\n\n Warnings:\n  • Risk of respiratory depression, especially with high doses or rapid administration.\n  • May cause muscle rigidity; consider premedication with a muscle relaxant.\n  • Use caution in patients with impaired respiratory function or head injuries.\n\n Monitoring:\n  • Continuous monitoring of respiratory and cardiovascular status is essential.\n  • Observe for signs of hypoventilation or apnea.\n  • Monitor for signs of opioid-induced muscle rigidity and take appropriate measures if necessary."
    },
    "rocuronium": {
      "label": "Rocuronium",
      "recDosage": "IV dose 0.6–1.2 mg/kg",
      "annotation": "Rocuronium is a non-depolarizing neuromuscular blocking agent used to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.\n\nConcentration:\n- 5 mL vial = 50 mg (10 mg/mL).\n\nIndications:\n- Rapid sequence and routine tracheal intubation.\n- Skeletal muscle relaxation during surgery.\n- Facilitation of mechanical ventilation in adequately sedated patients.\n\nDosage Considerations:\n- Adults:\n  - Intubation: 0.6 mg/kg IV; onset within 1–2 minutes; duration approximately 30–50 minutes. For rapid sequence intubation, doses up to 1.2 mg/kg IV may be used. \n  - Maintenance: 0.1–0.2 mg/kg IV as needed; or continuous infusion at rates of 4–16 mcg/kg/min. \n- Pediatrics:\n  - Intubation: 0.6 mg/kg IV; onset and duration may vary with age. \n  - Maintenance: 0.075–0.125 mg/kg IV as needed; or continuous infusion at rates of 7–10 mcg/kg/min. \n\nWarnings:\n- Risk of anaphylactic reactions; emergency treatment should be readily available. \n- Use with caution in patients with neuromuscular diseases (e.g., myasthenia gravis), electrolyte imbalances, or severe acid-base disturbances. \n- Continuous monitoring of neuromuscular function is recommended to assess depth of blockade and recovery. \n- Ensure adequate sedation and analgesia in paralyzed patients to prevent awareness during paralysis. \n\nMonitoring:\n- Neuromuscular transmission with a peripheral nerve stimulator.\n- Vital signs, including heart rate and blood pressure.\n- Signs of residual neuromuscular blockade during recovery."
    },
    "pediatricInfusion": {
      "label": "Pediatric infusion rate",
      "annotation": "Keep in mind that this formula is valid only if exactly 1 mL of the 1% drug solution is used for dilution; any change in this volume requires recalculating the final concentration! \n\nInfusion rate (mL/h) = (weight (kg) × 60 × dose (mcg/kg/min) / (drug concentration (%) × 10000)) × total volume after dilution (mL)."
    },
    "remifentanyl": {
      "label": "Remifentanil",
      "recDosageInduction": "0.5–1 mcg/kg/min",
      "recDosageInfusion": "0.05–2 mcg/kg/min",
      "annotation": "Remifentanil is a potent, ultra-short-acting synthetic opioid analgesic used during and after surgery to relieve pain and enhance the effects of general anesthesia. It is commonly administered intravenously and is not suitable for epidural or intrathecal administration due to formulation components. \n\nDosage Forms:\n- 1 mg per vial (lyophilized powder)\n- 2 mg per vial (lyophilized powder)\n- 5 mg per vial (lyophilized powder)\n\nIndications:\n- Analgesic component during induction and maintenance of general anesthesia for inpatient and outpatient procedures\n- Analgesic component of monitored anesthesia care in adult patients\n- Continuation as an analgesic into the immediate postoperative period under direct supervision\n\nDosage Considerations:\n- Dosages should be individualized based on patient factors such as age, weight, and concomitant medications.\n\nAdults:\n  • Induction of Anesthesia:\n    - With hypnotic or volatile agent: 0.5–1 mcg/kg/min IV infusion until after intubation; may administer an initial dose of 1 mcg/kg over 30–60 seconds if intubation is to occur less than 8 minutes after starting the infusion. \n  • Maintenance of Anesthesia:\n    - With nitrous oxide (66%): 0.25–0.5 mcg/kg/min IV infusion; may administer supplemental IV bolus doses of 0.5–1 mcg/kg every 2–5 minutes in response to light anesthesia or transient episodes of intense surgical stress. \n    - With isoflurane (starting at 0.5 minimum alveolar concentration [MAC]): 0.25 mcg/kg/min IV infusion; may administer supplemental IV bolus doses of 0.5–1 mcg/kg every 2–5 minutes. \n    - With sevoflurane (starting at 0.8 MAC): 0.25 mcg/kg/min IV infusion; may administer supplemental IV bolus doses of 0.5–1 mcg/kg every 2–5 minutes. \n  • Monitored Anesthesia Care:\n    - Initial IV infusion rate: 0.1 mcg/kg/min; may adjust by 0.025 mcg/kg/min every 5 minutes to balance analgesia and respiratory rate. \n\nPediatric Patients (1–12 years):\n  • Maintenance of Anesthesia:\n    - With halothane, sevoflurane, or isoflurane: 0.25 mcg/kg/min IV infusion; may administer supplemental IV bolus doses of 1 mcg/kg over 30–60 seconds as needed. \n\nWarnings and Precautions:\n- Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur; monitor patients closely, especially during initiation and following dosage increases. \n- Muscle Rigidity: May cause skeletal muscle rigidity, including chest wall rigidity, especially with rapid IV administration or high doses; manage with neuromuscular blocking agents if necessary. \n- Hypotension and Bradycardia: May cause decreases in blood pressure and heart rate; monitor cardiovascular status and manage accordingly. \n- Opioid-Induced Hyperalgesia: High doses or prolonged use may be associated with hyperalgesia; consider reducing the dose or discontinuing the infusion if this occurs. \n- Concomitant Use with CNS Depressants: Use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, or death; monitor patients closely. \n\nMonitoring:\n- Continuous monitoring of respiratory and cardiovascular status is required during administration. \n- Ensure resuscitative and intubation equipment, oxygen, and opioid antagonists are readily available. \n\nNote:\n- Due to its rapid onset and short duration of action, remifentanil should be administered only by persons specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids. \n- Not recommended as the sole agent for induction of anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia. \n- Upon discontinuation, alternative analgesics should be administered prior to discontinuation to ensure adequate postoperative analgesia."
    },
    "solutionConcentration": {
      "label": "Solution Concentration",
      "annotation": "Calculate percent concentration: (mass in g / volume in mL) * 100"
    },
    "devine": {
      "label": "Ideal Body Weight",
      "idealWeight": "Ideal Weight",
      "annotation": "Formula for calculating ideal body weight using the Devine method:\n\n- For men: IBW = 50 + 2.3 x (K * height (in centimeters) - 60);\n\n- For women: IBW = 45.5 + 2.3 x (K * height (in centimeters) - 60)\n\nK = 0.393701, the conversion factor from centimeters to inches."
    },
    "map": {
      "label": "Mean Arterial Pressure (MAP)",
      "result": "MAP",
      "annotation": "The mean arterial pressure (MAP) is calculated using the formula: 1/3*(SBP) + 2/3*(DBP) \n\nThe norm for MAP is considered to be between 70 and 110 mm Hg."
    },
    "potassiumDeficit": {
      "label": "Potassium Deficit Calculator",
      "drug_opt1": "7.5%",
      "drug_opt2": "4%",
      "potassiumDeficit": "Potassium deficit",
      "amountOfSolMl": "Potassium repletion via potassium chloride",
      "maxAmountDay": "Maximum daily intake of potassium chloride",
      "annotation": "1) Never give potassium I.M or rapid I.V push\n2) Never give more than 1.5 g KCl or 20 mmol of K+ over 1 hour"
    },
    "bicarbonateDeficit": {
      "label": "Calculate bicarbonate deficit",
      "bicarbonateDeficit": "Bicarbonate deficit",
      "solutionVolume": "Bicarbonate repletion via 4% NaHCO3 solution",
      "annotation": "NOTE: Sodium bicarbonate solution allows for rapid correction of acidosis, but the sodium cations contained in the solution further increase the osmolarity of the extracellular fluid, thereby aggravating cellular dehydration.\n\nCalculator use 24 mmol/L as normal level of bicarbonate so for correct answer current level should be lower"
    },
    "ett": {
      "label": "Calculate ET tube size for pediatric patients",
      "cuffedETT": "Cuffed ETT Diameter",
      "uncuffedETT": "Ununcuffed ETT Diameter",
      "ettDepth": "Insertion depth",
      "annotation": "This calculator utilizes a Cole`s formula for size: \n1) Size uncuffed = (age / 4) + 4 \n2) Size cuffed = (age / 4) + 3. \n\nInsertion depth formula = (age in years / 2) + 12"
    },
    "solutionDilution": {
      "label": "Solution Dilution Calculator",
      "annotation": "This calculator helps determine the necessary volumes to achieve a desired solution concentration.",
      "error": "Please ensure the desired concentration is less than the stock concentration"
    },
    "anionGap": {
      "label": "Calculate anion gap",
      "anionGap": "Anion Gap",
      "albuminAnionGap": "Albumin Corrected Anion Gap",
      "deltaGap": "Delta Gap",
      "albuminDeltaGap": "Albumin Corrected Delta Gap",
      "deltaRatio": "Delta Ratio",
      "albuminDeltaRatio": "Albumin Corrected Delta Ratio",
      "annotation": "Anion gap normal range is typically between 3 and 11 mmol/L, while anything below 3 mmol/L is considered abnormally low, and above 11 mmol/L is usually considered abnormally high. \n\nInterpretation of the delta ratio: \n1) Delta Ratio < 0.4: Hyperchloremic normal anion gap acidosis. \n2) Delta Ratio < 1: High anion gap (AG) & normal AG acidosis. \n3) Delta Ratio 1 to 2: Pure anion gap acidosis. \n- Lactic acidosis: average value 1.6. \n- Diabetic ketoacidosis (DKA) is more likely to have a ratio closer to 1 due to urine ketone loss. \n4) Delta Ratio > 2: High AG acidosis and a concurrent metabolic alkalosis or a pre-existing compensated respiratory acidosis."
    },
    "midazolam": {
      "label": "Midazolam",
      "annotation": "Midazolam is a short-acting benzodiazepine used for sedation and amnesia in medical procedures. It is also used for managing status epilepticus and as premedication before anesthesia.\n\n3 ml = 15mg.\n\nIndications:\n- Procedural sedation and anesthesia induction\n- Status epilepticus treatment (IM/IV)\n- Preoperative sedation\n\nDosage Considerations:\n- Pediatric oral sedation: Max 20 mg or 0.5 mg/kg\n- Pediatric IM sedation: 0.1 mg/kg\n- Pediatric IV sedation: 0.05-0.075 mg/kg\n- Pediatric intranasal: 0.2-0.25 mg/kg\n- Adult IV induction: 0.2 mg/kg\n- Adult IM premedication: 0.07 mg/kg\n- Adult IV sedation: 0.05 mg/kg\n\nWarnings:\n- Risk of respiratory depression, especially when combined with opioids or CNS depressants.\n- May cause dependence with prolonged use.\n- Use caution in elderly and renally impaired patients.\n\nMonitoring:\n- Continuous monitoring required for respiratory function.\n- Patients should be observed for signs of over-sedation or adverse reactions."
    }
  }
}
